Antibody response of mice and rabbits targeting HIV-1 using global panel DNA and SOSIP gp140 protein by Rohl, Kari Loni
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2016
Antibody response of mice and rabbits targeting




Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
Medical Immunology Commons, and the Virology Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Rohl, Kari Loni, "Antibody response of mice and rabbits targeting HIV-1 using global panel DNA and SOSIP gp140 protein" (2016).
Graduate Theses and Dissertations. 15800.
https://lib.dr.iastate.edu/etd/15800
	  Antibody	  response	  of	  mice	  and	  rabbits	  targeting	  HIV-­‐1	  using	  global	  panel	  DNA	  and	  









A	  thesis	  submitted	  to	  the	  graduate	  faculty	  
	  
in	  partial	  fulfillment	  of	  the	  requirements	  for	  the	  degree	  of	  
	  





Program	  of	  Study	  Committee:	  





















Copyright	  ©	  Kari	  Loni	  Rohl,	  2016.	  All	  rights	  reserved.	   	  
ii	  
TABLE	  OF	  CONTENTS	  
	  
	   	   	   	   	   	   	   	   	   	   	   	  	  Page	  
ACKNOWLEDGEMENTS	  .............................................................................................	  	   iii	  
ABSTRACT	  .................................................................................................................	  	   iv	  
CHAPTER	  1	  	   GENERAL	  INTRODUCTION	  ..............................................................	  	   1	  
	   Thesis	  Organization	  ............................................................................................	  	   1	  
	   Literature	  Review	  ...............................................................................................	  	   2	  
	   Figures	  ................................................................................................................	  	   9	  
	   References	  ..........................................................................................................	  	   12	  
CHAPTER	  2	   ANTIBODY	  RESPONSE	  OF	  MICE	  AND	  RABBITS	  PRIMED	  WITH	  	  
	   GLOBAL	  PANEL	  DNA	  AND	  BOOSTED	  WITH	  SOSIP	  GP140	  PROTEIN	  .......................	  	   18	  
	   Abstract	  ..............................................................................................................	  	   18	  
	   Introduction	  	  .......................................................................................................	  	   19	  
	   Results	  	  ................................................................................................................	  	   21	  
	   Discussion	  ...........................................................................................................	  	   24	  
	   Materials	  and	  Methods	  ......................................................................................	  	   26	  
	   Acknowledgement	  	  .............................................................................................	  	   29	  
	   Tables	  .................................................................................................................	  	   29	  
	   Figures	  ................................................................................................................	  	   30	  
	   References	  ..........................................................................................................	  	   38	  
CHAPTER	  3	   CONCLUSION	  AND	  FUTURE	  DIRECTIONS	  .......................................	  	   41	  
	   Conclusion	  	  ..........................................................................................................	  	   41	  
	   Future	  Directions	  	  ...............................................................................................	  	   42	  
	   References	  ..........................................................................................................	  	   43	  
APPENDIX	  A	   PRELIMINARY	  GENE	  GUN	  DATA	  .....................................................	  	   44	  
	   Conclusions	  	  .........................................................................................................	  	   44	  
	   Materials	  and	  Methods	  	  .....................................................................................	  	   44	  
	   Figures	  ................................................................................................................	  	   45	  
	   References	  ..........................................................................................................	  	   46	  
	  
iii	  
APPENDIX	  B	   HR1-­‐ID-­‐HR2	  ....................................................................................	  	   47	  
	   Conclusions	  	  .........................................................................................................	  	   47	  
	   Materials	  and	  Methods	  	  .....................................................................................	  	   48	  
	   Figures	  ................................................................................................................	  	   50	  
	   References	  ..........................................................................................................	  	   52	  
	  
	   	  
iv	  
ACKNOWLEDGEMENTS	  
I	  would	  first	  like	  to	  thank	  Dr.	  Cho	  for	  allowing	  me	  into	  his	  lab	  and	  giving	  me	  the	  
opportunity	  to	  work	  on	  this	  project.	  I	  would	  also	  like	  to	  thank	  Dr.	  Joan	  Cunnick,	  Dr.	  
Cathy	  Miller,	  Dr.	  James	  Roth,	  and	  Dr.	  Mark	  Ackermann	  for	  all	  of	  the	  advice	  and	  
assistance	  they	  provided	  me	  as	  my	  committee	  members.	  	  
I	  also	  want	  to	  thank	  all	  of	  the	  members	  of	  Cho	  lab.	  You	  are	  the	  best	  coworkers	  I	  
could	  have	  had.	  Special	  thanks	  to	  Dr.	  Marisa	  Banasik,	  for	  her	  critical	  editing	  of	  this	  paper	  
and	  her	  mentorship	  of	  me.	  	  
Finally,	  yet	  most	  importantly,	  I	  would	  like	  to	  thank	  my	  family.	  Mom,	  Dad,	  Gena	  
and	  Luke,	  you	  have	  all	  been	  so	  supportive	  and	  encouraging	  to	  me	  throughout	  my	  
studies,	  and	  especially	  during	  the	  writing	  of	  this	  thesis.	  I	  could	  not	  have	  done	  this	  
without	  you	  guys!	  	  
	  
	   	  
v	  
ABSTRACT	  
Human	  Immunodeficiency	  Virus	  type	  1	  (HIV-­‐1)	  is	  a	  highly	  variable	  virus	  that	  
continues	  to	  cause	  a	  worldwide	  pandemic.	  The	  search	  for	  a	  vaccine	  has	  focused	  on	  the	  
elicitation	  of	  broadly	  neutralizing	  antibodies	  (bnAbs),	  which	  can	  prevent	  the	  attachment	  
and/or	  entry	  of	  the	  majority	  of	  HIV	  strains.	  In	  this	  thesis,	  we	  attempt	  to	  elicit	  more	  
common	  neutralizing	  antibodies	  (nAbs),	  which	  are	  type-­‐specific	  in	  their	  ability	  to	  block	  
HIV	  infection.	  However,	  we	  propose	  to	  elicit	  a	  wide	  range	  of	  these	  type-­‐specific	  nAbs	  to	  
mimic	  the	  breadth	  of	  protection	  found	  in	  true	  bnAbs	  to	  protect	  the	  host	  from	  multiple	  
HIV	  strains.	  We	  immunized	  both	  mice	  and	  rabbits	  with	  a	  twelve	  virus	  panel,	  termed	  
global	  panel,	  that	  represents	  seven	  different	  HIV-­‐1	  clades.	  The	  immunizations	  were	  
performed	  using	  particle	  mediated	  epidermal	  delivery	  (PMED)	  loaded	  with	  plasmids	  
that	  could	  express	  the	  desired	  env	  proteins	  in	  vivo.	  The	  mice	  did	  not	  elicit	  any	  
neutralizing	  activity	  against	  tier	  1	  or	  tier	  2	  viruses.	  The	  rabbits	  had	  neutralization	  against	  






CHAPTER	  1:	  GENERAL	  INTRODUCTION	  
	  
Thesis	  Organization	  
This	  thesis	  is	  divided	  into	  three	  chapters.	  Chapter	  1	  is	  a	  literature	  review	  of	  HIV.	  
This	  contains	  a	  general	  overview	  of	  HIV	  including	  the	  history,	  the	  variability,	  the	  proteins	  
and	  structure,	  with	  a	  special	  focus	  on	  the	  envelope	  glycoprotein.	  Chapter	  1	  is	  followed	  
by	  a	  review	  of	  DNA	  vaccines,	  including	  how	  they	  produce	  proteins	  in	  vivo,	  the	  relative	  
safety	  of	  DNA	  vaccines,	  and	  the	  different	  administration	  techniques,	  focusing	  on	  gene	  
gun.	  	  
Chapter	  2	  is	  a	  manuscript	  in	  preparation	  entitled	  “Antibody	  response	  of	  mice	  
and	  rabbits	  primed	  with	  global	  panel	  DNA	  and	  boosted	  with	  BG505	  SOSIP	  gp140	  
protein.”	  This	  manuscript	  describes	  an	  attempt	  to	  induce	  neutralizing	  antibodies	  against	  
HIV	  using	  twelve	  different	  strains	  of	  HIV	  DNA	  delivered	  using	  a	  gene	  gun.	  The	  
contributions	  of	  each	  author	  are	  as	  follows:	  Kari	  Rohl	  performed	  all	  of	  the	  DNA	  
preparations,	  animal	  immunizations,	  and	  all	  the	  characterization	  assays.	  Feng	  Jiao	  made	  
the	  pseudoviruses	  for	  the	  neutralization	  assays,	  and	  assisted	  with	  the	  animal	  
immunizations.	  Kari	  Rohl	  and	  Michael	  W.	  Cho	  wrote	  and	  revised	  the	  manuscript.	  	  
Chapter	  3	  summarizes	  the	  conclusions	  and	  includes	  suggestions	  for	  future	  work.	  
This	  thesis	  also	  includes	  an	  appendix	  section	  containing	  other	  unpublished	  projects	  
where	  Kari	  Rohl	  was	  the	  primary	  investigator.	  	  
	   	  
2	  
Literature	  Review	  
Human	  Immunodeficiency	  Virus	  (HIV)	  was	  discovered	  in	  1983	  [1-­‐3].	  HIV	  type	  1	  
(HIV-­‐1)	  causes	  Acquired	  Immune	  Deficiency	  Syndrome	  (AIDS),	  which	  reduces	  the	  
immune	  system	  to	  negligible	  levels.	  HIV	  type	  2	  (HIV-­‐2)	  is	  morphologically	  similar,	  but	  is	  
antigenically	  distinct	  and	  more	  closely	  related	  to	  Simian	  Immunodeficiency	  Virus	  (SIV)	  
[4,5].	  HIV-­‐2	  is	  less	  virulent	  and	  limited	  to	  West	  Africa.	  For	  the	  remainder	  of	  this	  
document,	  HIV	  refers	  to	  HIV-­‐1.	  The	  most	  recent	  statistics	  on	  HIV	  from	  UNAIDS	  [6,7]	  
indicate	  that	  there	  were	  1.2	  million	  AIDS	  related	  deaths	  in	  2014;	  150,000	  of	  those	  
deaths	  were	  children	  under	  the	  age	  of	  15.	  Two	  million	  people	  were	  infected	  with	  HIV,	  
and	  nearly	  37	  million	  people	  are	  currently	  living	  with	  HIV	  as	  of	  2014.	  	  
HIV	  is	  split	  into	  four	  main	  groups:	  M	  (major),	  O	  (outlier),	  N	  (non-­‐	  M	  or	  O),	  and	  P	  
(Fig	  1.1).	  Group	  M	  is	  the	  pandemic	  group	  and	  is	  divided	  into	  ten	  clades	  (A-­‐K)	  (reviewed	  
in	  [8]).	  HIV	  is	  highly	  variable,	  and	  in	  group	  M	  alone	  there	  is	  a	  25-­‐35%	  divergence	  in	  
sequence	  between	  the	  clades,	  and	  up	  to	  20%	  sequence	  divergence	  within	  any	  clade.	  
Infections	  from	  clade	  C	  represent	  nearly	  half	  (48%)	  of	  those	  worldwide,	  and	  clade	  C	  is	  
the	  prevalent	  strain	  in	  Africa	  and	  India.	  Clade	  B	  has	  the	  highest	  number	  of	  complete	  
sequences	  as	  it	  is	  more	  prevalent	  in	  developed	  countries	  with	  easier	  access	  to	  patient	  
samples,	  but	  this	  clade	  only	  accounts	  for	  about	  12%	  of	  infections	  worldwide	  [9,10].	  
Infection	  by	  a	  second	  strain	  of	  HIV	  is	  possible	  and	  results	  in	  numerous	  HIV	  interclade	  





HIV	  is	  a	  member	  of	  the	  Lentivirus	  genus	  and	  the	  Retroviridae	  family.	  HIV	  is	  an	  
enveloped	  virus	  containing	  two	  copies	  of	  a	  single-­‐stranded,	  positive	  sense	  RNA	  that	  is	  
9.2k	  nucleotides	  long	  [14,15].	  It	  encodes	  typical	  retrovirus	  structural	  proteins:	  Gag,	  Pol,	  
and	  Env.	  Additionally,	  HIV	  expresses	  regulatory	  proteins	  Tat	  and	  Rev,	  as	  well	  as	  several	  
accessory	  proteins:	  Nef,	  Vif,	  Vpr,	  and	  Vpu	  (Fig	  1.2).	  	  
Gag	  is	  expressed	  from	  an	  unspliced	  viral	  mRNA.	  This	  membrane-­‐associated	  Gag	  
polyprotein	  results	  in	  the	  virion	  budding	  from	  the	  infected	  cell.	  The	  Gag	  polyprotein	  is	  
cleaved	  [16,17],	  yielding	  the	  matrix	  (MA),	  capsid	  (CA),	  and	  nucleocapsid	  (NC)	  and	  p6	  
proteins.	  MA	  proteins	  increase	  stability	  by	  attaching	  to	  the	  inner	  portion	  of	  the	  lipid	  
bilayer.	  A	  small	  portion	  of	  the	  MA	  proteins	  attaches	  to	  the	  complex	  that	  shuttles	  the	  
viral	  DNA	  into	  the	  host	  nucleus	  [18-­‐22].	  CA	  forms	  the	  conical	  shaped	  core	  of	  viral	  
particles	  (Fig	  1.3).	  The	  NC	  protein	  ensures	  that	  viral	  RNA	  is	  incorporated	  into	  the	  new	  
virions	  [23,24].	  NC	  also	  plays	  a	  role	  in	  reverse	  transcription	  [25-­‐27].	  The	  p6	  region	  of	  Gag	  
is	  important	  for	  the	  inclusion	  of	  viral	  protein	  R	  (Vpr)	  into	  the	  new	  virion	  and	  for	  budding	  
[28,29].	  
The	  Pol	  polyprotein	  coding	  region	  overlaps	  with	  the	  Gag	  coding	  region,	  though	  
they	  use	  different	  reading	  frames.	  During	  the	  maturation	  process,	  the	  protease	  cleaves	  
the	  Pol	  polypeptide	  into	  the	  protease	  (PR),	  reverse	  transcriptase	  (RT),	  and	  integrase	  (IN)	  
proteins.	  HIV	  RT	  makes	  a	  double-­‐stranded	  DNA	  copy	  from	  the	  single-­‐stranded	  viral	  RNA.	  
As	  RT	  does	  not	  contain	  a	  proof-­‐reading	  mechanism,	  there	  is	  a	  high	  error	  rate,	  resulting	  
4	  
in	  several	  point	  mutations	  in	  each	  newly	  made	  genome	  copy	  [30-­‐34].	  The	  IN	  is	  
responsible	  for	  inserting	  the	  proviral	  DNA	  into	  the	  host	  cell	  DNA	  [35,36].	  	  
Tat	  (transactivator	  of	  transcription)	  is	  the	  regulatory	  protein	  that	  is	  required	  for	  
HIV	  replication	  [37,38].	  Tat	  binds	  RNA	  and	  promotes	  the	  production	  of	  full-­‐length	  
transcripts	  [39-­‐41].	  Rev	  regulates	  the	  transition	  from	  early	  to	  the	  late	  phase	  gene	  
expression	  [42,43].	  Rev	  also	  exports	  unspliced	  or	  incompletely	  spliced	  viral	  RNA	  from	  
the	  nucleus	  [44].	  	  
Negative	  regulation	  factor	  (Nef)	  is	  the	  initial	  viral	  protein	  that	  accumulates	  in	  an	  
infected	  cell.	  Nef	  has	  many	  different	  functions,	  one	  of	  which	  is	  the	  down-­‐regulation	  of	  
CD4,	  as	  cell-­‐surface	  localized	  CD4	  inhibits	  the	  budding	  and	  Env	  expression	  of	  new	  virions	  
[1,3].	  Vpr	  assists	  in	  the	  infection	  of	  non-­‐dividing	  cells	  by	  helping	  it	  to	  localize	  the	  
preintegration	  complex	  (PIC)	  to	  the	  nucleus	  [45].	  Viral	  protein	  U	  (Vpu)	  enhances	  viral	  
budding.	  Viral	  infectivity	  factor	  (Vif)	  prevents	  HIV	  inactivation	  by	  interfering	  with	  
APOBEC3G	  [1,4],	  which	  is	  an	  innate	  antiviral	  protein	  that	  will	  terminate	  the	  viral	  life	  
cycle	  [6].	  	  
	  
HIV	  envelope	  	  
The	  Env	  glycoprotein	  (gp)	  is	  originally	  expressed	  as	  a	  160kD	  protein	  from	  a	  single	  
mRNA.	  It	  is	  made	  in	  the	  endoplasmic	  reticulum	  and	  transports	  through	  the	  Golgi	  
apparatus,	  where	  glycosylation	  occurs.	  Here,	  25-­‐30	  complex	  N-­‐linked	  carbohydrate	  side	  
chains	  are	  added	  to	  Asp	  residues.	  This	  process	  is	  required	  for	  newly	  formed	  virions	  to	  be	  
infectious	  [46].	  The	  cellular	  protease	  furin	  cleaves	  the	  original	  gp160	  protein	  into	  two	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subunits:	  	  gp41	  and	  gp120.	  These	  subunits	  are	  non-­‐covalently	  bound,	  and	  present	  as	  a	  
trimer	  that	  is	  embedded	  in	  the	  virion	  surface	  as	  well	  as	  infected	  cells.	  gp41	  contains	  the	  
transmembrane	  domain	  and	  the	  fusion	  peptide,	  while	  gp120	  engages	  the	  cellular	  
receptor	  and	  co-­‐receptor	  [9].	  
HIV	  binds	  to	  its	  major	  receptor,	  CD4,	  with	  a	  specific	  structural,	  but	  non-­‐linear	  
domain	  called	  the	  CD4	  binding	  site	  (CD4bs)	  [11].	  CD4	  is	  an	  immunoglobulin	  (Ig)-­‐	  like	  
protein	  that	  is	  expressed	  on	  helper	  T	  cells	  and	  primary	  macrophages.	  The	  binding	  of	  the	  
CD4	  is	  not	  enough	  for	  viral	  fusion	  and	  entry.	  HIV	  also	  requires	  co-­‐receptor	  binding	  to	  
either	  CCR5	  or	  CXCR4	  [14].	  The	  binding	  of	  CD4	  causes	  extreme	  conformational	  changes	  
in	  the	  Env	  that	  allow	  co-­‐receptor	  binding	  and	  subsequent	  viral	  entry	  into	  the	  host	  cell	  
[16].	  gp120	  contains	  five	  variable	  loops,	  labeled	  V1-­‐	  V5.	  The	  V3	  loop	  is	  not	  involved	  in	  
binding	  to	  CD4,	  but	  it	  does	  interact	  with	  the	  co-­‐receptors	  CCR5	  and	  CXCR4	  and	  is	  
partially	  responsible	  for	  the	  susceptibility	  of	  different	  cells	  to	  specific	  strains	  of	  HIV	  
[18,20].	  	  
The	  primary	  function	  of	  gp41	  is	  to	  facilitate	  the	  fusion	  of	  the	  viral	  and	  cellular	  
membranes.	  Before	  gp120-­‐CD4	  attachment,	  gp41	  is	  hidden	  inside	  of	  the	  viral	  envelope.	  
However,	  once	  CD4	  binding	  has	  occurred,	  the	  gp41	  fusion	  peptide	  is	  exposed	  which,	  
due	  to	  its	  hydrophobic	  nature,	  inserts	  into	  the	  host	  cell	  membrane	  [23].	  This	  insertion	  
fastens	  the	  virion	  to	  the	  host	  cell	  and	  allows	  for	  the	  fusion	  peptides	  to	  change	  into	  a	  six-­‐
helix	  bundle	  [24,25,27].	  Because	  the	  fusion	  peptide	  is	  buried	  in	  the	  host	  cell	  membrane,	  
and	  the	  transmembrane	  region	  of	  gp41	  is	  lodged	  in	  the	  virion	  membrane,	  the	  formation	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of	  the	  six-­‐helix	  bundle	  brings	  the	  two	  membranes	  together	  and	  a	  fusion	  pore	  forms	  [25-­‐
28],	  allowing	  the	  viral	  genome	  to	  enter	  the	  host	  cell.	  	  
	  
DNA	  vaccines	  
It	  was	  first	  demonstrated	  in	  the	  1990s	  that	  direct	  inoculation	  of	  an	  antigen-­‐
expressing	  DNA	  plasmid	  induced	  humoral	  and	  cellular	  immunity	  [28-­‐30,32-­‐34].	  The	  
general	  strategy	  for	  DNA	  immunizations	  is	  the	  same,	  no	  matter	  the	  immunization	  route	  
(Fig	  1.4).	  The	  plasmid	  vector	  has	  a	  high-­‐efficiency	  promoter	  that	  guides	  the	  transcription	  
of	  the	  desired	  antigen	  in	  a	  cell’s	  nucleus.	  This	  DNA	  plasmid	  is	  injected	  into	  the	  skin	  or	  
muscle,	  where	  it	  will	  enter	  a	  cell	  and	  synthesize	  the	  antigen.	  The	  plasmid	  antigen	  is	  
translated	  and	  expressed	  by	  the	  transfected	  cells,	  and	  induces	  an	  immune	  response	  
against	  the	  antigen.	  	  
The	  intracellular	  transcription	  and	  translation	  of	  plasmid	  DNA	  mimic	  the	  
replication	  of	  a	  virus	  during	  infection.	  Both	  systems	  require	  cellular	  machinery	  to	  cross	  
the	  plasma	  membrane	  and	  to	  translate	  their	  proteins.	  Since	  the	  processing	  of	  the	  
plasmid	  protein	  is	  the	  same	  as	  the	  viral	  proteins,	  it	  results	  in	  antigen	  that	  is	  likely	  folded	  
in	  its	  native	  conformation.	  Since	  this	  imitates	  both	  the	  glycosylation	  and	  the	  post-­‐
translational	  modifications,	  it	  gives	  rise	  to	  products	  that	  resemble	  a	  natural	  infection	  
more	  closely	  than	  protein	  immunization,	  and	  it	  should	  favor	  the	  production	  of	  
neutralizing	  antibodies.	  	  
DNA	  immunizations	  overcome	  the	  safety	  risks	  that	  are	  associated	  with	  live	  
(attenuated)	  vaccines.	  Live	  attenuated	  vaccines	  have	  the	  ability	  to	  revert	  to	  their	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virulent	  wild	  type	  status,	  and	  they	  also	  have	  the	  potential	  to	  spread	  to	  unintended	  
individuals	  [30-­‐35].	  DNA	  vaccinations	  do	  not	  have	  the	  genetic	  material	  to	  revert	  to	  a	  
virulent	  virus.	  They	  only	  contain	  the	  limited	  genetic	  material	  encoding	  a	  specific	  antigen	  
that	  is	  inserted	  into	  the	  immunized	  plasmid.	  	  
There	  are	  many	  different	  ways	  of	  vaccinating	  with	  DNA.	  The	  most	  common	  are	  
intra-­‐muscular	  DNA	  injection	  (IM)	  or	  by	  particle	  mediated	  epidermal	  delivery	  (PMED)	  
using	  a	  “gene	  gun.”	  Gene	  gun	  inoculation	  requires	  far	  less	  DNA	  than	  needle	  injection	  	  
because	  it	  is	  very	  effective	  at	  propelling	  the	  plasmid	  into	  the	  cells	  of	  the	  epidermis.	  
Gene	  gun	  bombardment	  primarily	  elicits	  a	  humoral	  response	  [35-­‐37],	  whereas	  injection	  
into	  muscle	  results	  in	  a	  strong	  cellular-­‐mediated	  response	  without	  much	  Ab	  response	  
[37-­‐39].	  	  
There	  have	  been	  several	  gene	  gun	  DNA	  vaccines	  that	  have	  been	  successful	  in	  
eliciting	  protective	  immunity	  against	  viral	  infections	  such	  as	  rabies	  [39-­‐42],	  influenza	  
[42,43,47,48]	  and	  foot-­‐and-­‐mouth	  disease	  [44,49].	  There	  have	  also	  been	  a	  few	  studies	  
that	  focus	  on	  developing	  a	  strong	  Ab	  response	  against	  HIV	  with	  most	  targeting	  gp120	  or	  
gp41	  protein	  [1,3,50-­‐52].	  Studies	  show	  the	  antibody	  production	  is	  lower	  than	  protein	  
alone,	  but	  when	  boosted	  with	  protein,	  the	  neutralization	  activity	  is	  higher	  than	  with	  
either	  alone	  [53-­‐55].	  	  
	  
HIV	  vaccines	  
To	  combat	  infections	  one	  can	  either	  resort	  to	  treatment	  following	  infection	  or	  
prevention	  to	  block	  infection	  at	  its	  outset.	  HIV	  is	  historically	  difficult	  to	  treat	  due	  to	  the	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error	  prone	  replication	  (reviewed	  in	  [56]),	  which	  quickly	  yields	  HIV	  strains	  resistant	  to	  
certain	  treatments	  [57].	  However	  there	  has	  been	  some	  success	  with	  antiretroviral	  
therapy	  (ART)	  and	  the	  more	  recent	  highly	  active	  ART	  (HAART).	  ART	  suppresses	  the	  
number	  of	  HIV	  virions	  circulating,	  giving	  the	  immune	  system	  a	  chance	  to	  fight	  off	  
infections	  on	  its	  own	  and	  reducing	  the	  risk	  of	  transmitting	  the	  virus	  to	  others.	  
Unfortunately,	  current	  ART	  cannot	  get	  rid	  of	  all	  of	  the	  HIV	  as	  some	  remain	  hidden	  in	  
reservoirs	  that	  ART	  and	  the	  immune	  system	  cannot	  access	  [58-­‐60].	  This	  results	  in	  a	  
lifetime	  of	  consistent	  use	  of	  expensive	  medications.	  	  
A	  subset	  of	  individuals	  who	  have	  been	  chronically	  infected	  with	  HIV	  will	  develop	  
broadly	  neutralizing	  antibodies	  (bnAbs).	  These	  Abs	  are	  able	  to	  bind	  to	  the	  majority	  of	  
HIV	  strains	  and	  prevent	  them	  entering	  the	  host	  cell,	  thus	  neutralizing	  the	  virus	  [61,62].	  
Individuals	  who	  elicit	  bnAbs	  tend	  to	  have	  consistently	  low	  levels	  of	  viremia	  [63].	  HIV	  
infection	  could	  be	  prevented	  altogether	  if	  a	  vaccine	  induced	  bnAbs.	  For	  HIV	  vaccine	  
development,	  we	  focus	  on	  the	  env	  glycoprotein	  because	  it	  is	  the	  only	  portion	  exposed	  
before	  infection.	  	  
There	  has	  been	  only	  a	  handful	  of	  vaccine	  trials	  that	  progressed	  to	  Phase	  IIb	  and	  
Phase	  III	  clinical	  trials.	  Of	  those,	  only	  one	  clinical	  trial	  successfully	  induced	  some	  
protection	  against	  HIV.	  The	  RV144	  vaccine	  used	  a	  combination	  of	  two	  previously	  failed	  
HIV	  immunogens	  [64].	  They	  primed	  with	  a	  recombinant	  canarypox	  viral	  vector	  
containing	  the	  env,	  gag,	  and	  pro	  genes	  (ALVAC-­‐HIV)	  then	  boosted	  with	  a	  gp120	  protein	  
vaccine	  (AIDSVAX-­‐B/E).	  This	  vaccination	  schedule	  lowered	  the	  rate	  of	  infection	  by	  31.2%	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as	  compared	  with	  the	  group	  given	  the	  placebo.	  However,	  it	  did	  not	  affect	  the	  viral	  load	  
of	  those	  who	  did	  become	  infected	  during	  the	  trial.	  	  
A	  vaccine	  is	  considered	  by	  many	  scientists	  to	  be	  the	  best	  way	  to	  conquer	  the	  HIV	  
pandemic.	  ART	  is	  becoming	  more	  efficient,	  but	  preventative	  measures	  are	  a	  more	  cost	  





Fig	  1.1:	  HIV	  phylogenetic	  tree	  depicting	  groups	  and	  clades.	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Fig	  1.3:	  Structure	  of	  the	  HIV	  virion.	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CHAPTER	  2:	  ANTIBODY	  RESPONSE	  OF	  MICE	  AND	  RABBITS	  PRIMED	  WITH	  
GLOBAL	  PANEL	  DNA	  AND	  BOOSTED	  WITH	  SOSIP	  GP140	  PROTEIN	  
A	  manuscript	  in	  preparation	  
Kari	  Rohl,	  Feng	  Jiao,	  and	  Michael	  W.	  Cho	  
	  
Abstract	  
The	  search	  for	  an	  HIV-­‐1	  vaccine	  that	  induces	  broadly	  neutralizing	  antibodies	  
(bnAbs)	  capable	  of	  targeting	  multiple	  HIV	  strains	  has	  been	  unsuccessful.	  Based	  on	  
research	  by	  deCamp	  et	  al.	  [1],	  we	  proposed	  an	  immunization	  strategy	  with	  a	  diverse	  
group	  of	  HIV	  env	  genes	  that	  are	  statistically	  shown	  to	  be	  a	  representative	  sample	  of	  the	  
global	  epidemic.	  We	  hypothesized	  that	  even	  though	  this	  strategy	  may	  not	  elicit	  true	  
bnAbs,	  it	  could	  generate	  type-­‐specific	  neutralizing	  Abs	  targeting	  many	  different	  HIV	  
clades,	  therefore	  protecting	  the	  host	  against	  infection.	  Mice	  and	  rabbits	  were	  
immunized	  with	  12	  different	  HIV	  envs	  from	  several	  different	  clades	  representing	  the	  
potential	  breadth	  of	  infection.	  Immunizations	  were	  primed	  with	  submixtures	  of	  env	  
DNA	  using	  a	  gene	  gun,	  and	  a	  subsequent	  SOSIP	  gp140	  protein	  boosts.	  There	  was	  no	  
neutralizing	  activity	  from	  the	  mouse	  serum	  against	  tier	  1	  viruses,	  or	  against	  the	  tier	  2	  
global	  panel	  viruses.	  The	  rabbits	  showed	  neutralization	  against	  a	  single	  tier	  1	  virus,	  and	  






A	  significant	  problem	  for	  vaccine	  development	  against	  Human	  
Immunodeficiency	  Virus	  type	  1	  (HIV-­‐1)	  is	  the	  difficulty	  in	  eliciting	  broadly	  neutralizing	  
antibodies	  (bnAb)	  against	  the	  many	  circulating	  viral	  strains.	  The	  only	  target	  for	  vaccines	  
against	  HIV	  is	  the	  envelope	  protein	  (env)	  as	  this	  is	  the	  only	  portion	  of	  the	  virus	  exposed	  
and	  available	  for	  antibodies	  (Abs)	  to	  bind.	  HIV	  env	  consists	  of	  two	  main	  proteins	  
arranged	  in	  non-­‐covalent	  heterotrimer:	  gp120	  and	  gp41.	  gp120	  is	  outer	  portion	  of	  the	  
env	  and	  contains	  the	  binding	  site	  for	  the	  CD4	  receptor.	  After	  gp120	  binds	  CD4,	  the	  env	  
undergoes	  drastic	  conformational	  changes	  to	  reveal	  gp41,	  which	  can	  now	  insert	  itself	  
into	  the	  host	  cell	  membrane	  and	  begin	  the	  fusion	  process	  to	  permit	  HIV	  virion	  entry.	  	  
DNA	  immunization	  has	  been	  investigated	  since	  the	  1990s	  [2-­‐5].	  A	  plasmid	  
encoding	  for	  a	  protein	  is	  injected	  into	  the	  skin	  or	  muscle.	  Once	  the	  plasmid	  enters	  a	  cell,	  
it	  is	  trafficked	  into	  the	  nucleus	  and	  directs	  the	  synthesis	  of	  the	  specified	  antigen.	  
Resulting	  protein	  production	  is	  similar	  to	  viral	  protein	  replication	  during	  a	  natural	  
infection.	  Both	  rely	  on	  host	  machinery	  to	  translate	  and	  transport	  the	  products.	  
However,	  the	  utilization	  of	  a	  DNA	  plasmid	  encoding	  a	  protein	  immunogen	  is	  significantly	  
safer	  to	  deliver	  a	  protein	  antigen	  than	  a	  live	  attenuated	  vaccine,	  as	  there	  is	  no	  potential	  
for	  virulence	  reversion	  [6].	  There	  are	  several	  different	  ways	  to	  deliver	  a	  DNA	  vaccine;	  
the	  two	  most	  common	  ways	  are	  through	  intra-­‐muscular	  DNA	  injection	  (IM)	  and	  by	  
particle	  mediated	  epidermal	  delivery	  (PMED)	  using	  a	  gene	  gun.	  The	  gene	  gun	  is	  
extremely	  effective	  at	  injecting	  the	  plasmid	  DNA	  into	  the	  cells	  of	  the	  epidermis	  without	  
using	  needles,	  and	  requires	  far	  less	  DNA	  than	  needle	  injection	  [7].	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Eliciting	  bnAbs	  is	  a	  major	  goal	  for	  HIV	  vaccination	  studies.	  Studies	  have	  shown	  
that	  the	  passive	  transfer	  of	  bnAbs	  taken	  from	  chronically	  infected	  HIV	  patients	  can	  
provide	  protection	  against	  most	  routes	  of	  infection	  [8-­‐12].	  Characterization	  of	  these	  
bnAbs	  revealed	  they	  target	  highly	  conserved	  regions,	  such	  as	  the	  base	  of	  the	  V3	  loop	  
[13],	  the	  CD4	  binding	  site	  [14],	  and	  the	  membrane-­‐proximal	  external	  region	  (MPER)	  of	  
gp41	  [15].	  The	  development	  of	  bnAbs	  correlates	  with	  a	  high	  viral	  load	  and	  chronic	  
infection,	  which	  allows	  the	  B	  cells	  sufficient	  time	  to	  undergo	  extensive	  somatic	  
hypermutation	  [16].	  	  
A	  vaccine	  strategy	  is	  needed	  that	  can	  mimic	  infection	  with	  diverse	  antigens	  over	  
an	  extended	  period	  of	  time.	  Polyvalent	  vaccines	  composed	  of	  multiple	  different	  env	  
proteins	  produce	  a	  broader	  nAb	  response	  than	  a	  monovalent	  env	  protein	  in	  rabbits	  and	  
macaques	  [17-­‐19].	  The	  variability	  in	  the	  multiple	  env	  proteins	  could	  assist	  in	  selecting	  
for	  a	  consensus	  epitope,	  such	  as	  the	  conserved	  regions	  in	  the	  env,	  as	  well	  as	  with	  B	  cell	  
cross-­‐linking.	  	  
In	  a	  study	  by	  deCamp	  et	  al.	  [1],	  the	  authors	  determined	  that	  there	  were	  twelve	  
virus	  strains	  that	  accurately	  represent	  the	  global	  epidemic	  of	  currently	  circulating	  
strains,	  which	  they	  termed	  the	  global	  panel.	  They	  tested	  219	  env-­‐pseudotyped	  viruses	  
against	  the	  serum	  of	  205	  chronically	  infected	  individuals,	  collected	  from	  around	  the	  
globe.	  The	  twelve	  strains	  that	  they	  determined	  statistically	  represented	  the	  spectrum	  of	  
HIV	  are	  highly	  sensitive	  to	  the	  known	  bnAbs.	  Immunization	  with	  these	  twelve	  strains	  
could	  potentially	  produce	  nAbs	  that	  cover	  the	  spectrum	  of	  HIV	  strains.	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Based	  on	  these	  studies,	  we	  proposed	  that	  a	  polyvalent	  immunization	  would	  
induce	  nAbs	  that	  cover	  the	  possible	  breadth	  of	  HIV	  infection.	  We	  hypothesized	  that	  DNA	  
immunizations	  using	  the	  gene	  gun	  would	  effectively	  deliver	  multiple	  HIV	  env	  plasmids,	  
thus	  potentially	  inducing	  broader	  neutralization	  activity	  than	  a	  single	  env	  immunogen.	  
Using	  the	  global	  panel	  DNA	  to	  elicit	  nAbs	  against	  a	  broad	  spectrum	  of	  HIV	  strains	  would	  




We	  divided	  the	  global	  panel	  envs	  into	  six	  groups	  based	  on	  their	  clade	  containing	  
between	  one	  and	  three	  strains	  (Table	  2.1).	  The	  gp160	  plasmid	  DNA	  of	  each	  of	  the	  
groups	  was	  mixed	  and	  loaded	  together	  onto	  the	  gene	  gun	  bullets.	  	  
For	  the	  first	  immunization,	  we	  immunized	  with	  one	  bullet	  each	  from	  group	  1,	  
group	  3,	  and	  group	  6	  (Fig	  2.1).	  The	  second	  immunization	  was	  performed	  with	  one	  bullet	  
each	  from	  group	  2,	  group	  4	  and	  group	  5.	  The	  antibody	  titers	  against	  gp120	  after	  the	  first	  
and	  second	  immunization	  reached	  103	  (Fig	  2.2a).	  Unfortunately,	  these	  did	  not	  increase	  
after	  the	  third	  (groups	  1,	  3,	  and	  6)	  or	  the	  fourth	  (groups	  2,	  4,	  and	  5)	  immunizations	  as	  
anticipated.	  Although	  the	  titers	  did	  not	  increase,	  neither	  did	  they	  decrease	  after	  a	  two-­‐
week	  waiting	  period.	  We	  followed	  the	  gene	  gun	  DNA	  immunizations	  with	  two	  protein	  
boosts	  using	  30ug	  of	  SOSIP	  gp140	  adjuvanted	  with	  zinc	  chitosan	  (ZnCh).	  After	  the	  
second	  protein	  boost,	  corresponding	  to	  the	  sixth	  immunization	  and	  collected	  at	  the	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terminal	  bleed,	  the	  antibody	  titer	  against	  gp140	  reached	  above	  106	  and	  105	  against	  
gp120	  (Fig	  2.2	  a	  and	  b).	  
Next,	  we	  analyzed	  whether	  any	  neutralizing	  activity	  was	  present	  in	  the	  sera	  
against	  laboratory-­‐adapted	  (tier	  1)	  pseudoviruses,	  which	  are	  considered	  easy	  to	  
neutralize,	  and	  later	  against	  tier	  2,	  global	  panel	  pseudoviruses,	  which	  are	  primary	  
isolates	  and	  harder	  to	  neutralize	  [20].	  We	  tested	  pooled	  sera	  from	  after	  the	  fourth	  
immunization	  against	  several	  tier	  1	  pseudoviruses:	  SS1196,	  MN.3,	  MW965,	  DH12,	  Q23,	  
and	  Bal.26.	  No	  neutralization	  activity	  was	  observed	  (Fig	  2.3).	  In	  fact,	  we	  saw	  
enhancement	  of	  viral	  infectivity,	  which	  is	  common	  for	  non-­‐neutralizing	  serum	  (YQ,	  KLR,	  
and	  MWC	  unpublished	  observation).	  The	  tier	  1	  viruses	  were	  not	  tested	  with	  the	  after	  
the	  sixth	  immunization	  serum	  due	  to	  a	  lack	  of	  serum	  from	  the	  mice.	  
Serum	  was	  tested	  for	  neutralization	  against	  the	  global	  panel	  pseudoviruses	  after	  
the	  sixth	  collection.	  There	  was	  no	  neutralizing	  activity	  (Fig	  2.4).	  BJOX002000	  had	  some	  
weak	  neutralization	  (slightly	  above	  50%)	  at	  the	  initial	  1:20	  dilution,	  but	  quickly	  dropped	  
off	  at	  the	  lower	  dilutions.	  Most	  of	  the	  others	  showed	  enhancement	  of	  the	  serum	  at	  the	  
initial	  dilution.	  	  
	  
Rabbit	  immunizations	  
The	  rabbits	  were	  immunized	  similarly	  to	  the	  mice.	  Even	  though	  the	  mice	  
immunization	  data	  was	  generally	  negative,	  neutralization	  from	  the	  rabbit	  serum	  may	  be	  
more	  likely	  due	  to	  their	  longer	  CDR3	  regions	  as	  compared	  to	  the	  CDR3	  region	  mice	  [21],	  
which	  is	  a	  required	  hallmark	  of	  some	  anti-­‐HIV	  antibodies.	  The	  dosage	  of	  DNA	  and	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protein	  was	  increased	  given	  the	  larger	  animal	  size,	  and	  the	  timeline	  was	  extended	  (Fig	  
5:).	  The	  rabbits	  were	  immunized	  with	  6ug	  of	  DNA	  every	  two	  weeks,	  and	  serum	  was	  
collected	  before	  the	  subsequent	  immunization,	  for	  a	  total	  of	  five	  DNA	  immunizations.	  
The	  first	  four	  were	  global	  panel	  groups,	  as	  described	  for	  mice.	  The	  fifth	  was	  SOSIP	  gp140	  
DNA.	  The	  rabbits	  were	  boosted	  with	  100ug	  of	  gp140	  protein	  on	  ZnCh	  on	  week	  24	  and	  
on	  week	  26.	  	  
The	  antibody	  titer	  from	  the	  DNA	  immunizations	  alone	  was	  unexpected	  as	  there	  
was	  no	  observed	  gp120	  or	  gp140	  specific	  response	  (Fig	  2.6	  a	  and	  b).	  After	  the	  first	  
protein	  boost	  (sixth	  immunization),	  the	  antibody	  titer	  rose	  to	  at	  least	  104	  for	  all	  the	  
rabbits	  against	  gp120,	  and	  105	  against	  gp140.	  The	  second	  boost	  with	  gp140	  increased	  
the	  titer	  to	  106	  against	  both	  gp120	  and	  gp140.	  	  
All	  neutralization	  assays	  were	  performed	  with	  serum	  collected	  after	  the	  seventh	  
immunization	  (second	  gp140	  ZnCh	  boost).	  First,	  we	  tested	  the	  serum	  against	  three	  tier	  1	  
viruses:	  SF162,	  DH12,	  and	  Bal.26	  (Fig	  2.7).	  All	  three	  rabbits	  could	  neutralize	  SF162.	  None	  
of	  the	  rabbit	  sera	  could	  neutralize	  DH12,	  and	  rabbit	  2	  (Rb	  2)	  was	  able	  to	  weakly	  
neutralize	  Bal.26.	  We	  next	  tested	  pseudoviruses	  produced	  from	  the	  global	  panel	  (Fig	  
2.8).	  None	  of	  the	  twelve	  viruses	  were	  neutralized.	  Five	  of	  the	  twelve	  assays	  showed	  the	  
same	  viral	  infectivity	  enhancement	  observed	  in	  the	  mouse	  serum,	  while	  the	  other	  seven	  






Studies	  have	  shown	  that	  a	  polyvalent	  DNA	  vaccine	  is	  more	  effective	  at	  creating	  
neutralizing	  antibodies	  than	  their	  monovalent	  counterparts	  [17,18,22].	  We	  grouped	  the	  
strains	  by	  clade,	  then	  immunized	  with	  three	  different	  clades	  per	  immunization	  (Table	  1).	  
By	  doing	  this,	  we	  attempted	  to	  activate	  a	  wider	  variety	  of	  antibodies,	  thus	  perhaps	  
increasing	  the	  likelihood	  of	  B	  cell	  cross-­‐reactivity	  [23,24].	  The	  sequential	  immunization	  
of	  different	  HIV	  env	  (Figs	  2.1	  and	  2.5)	  should	  be	  more	  advantageous	  than	  simultaneous	  
immunization	  of	  all	  the	  same	  env	  strains	  [24].	  This	  will	  help	  to	  guide	  the	  antibodies	  
toward	  conserved	  regions	  of	  the	  env,	  and	  thus	  be	  more	  likely	  to	  yield	  nAbs.	  	  
The	  Ab	  titer	  (Fig	  2.2)	  in	  mice	  greatly	  increased	  in	  response	  to	  the	  DNA	  
immunizations	  and	  increased	  more	  so	  after	  protein	  boosts.	  The	  titer	  against	  gp140	  after	  
the	  second	  protein	  boost	  is	  similar	  to	  what	  we	  have	  observed	  after	  two	  protein	  
immunizations	  with	  gp140	  on	  ZnCh	  alone.	  DNA	  vaccines	  often	  produce	  lower	  titers	  of	  
Abs	  than	  protein	  vaccines.	  However,	  vaccinations	  that	  are	  primed	  with	  DNA	  then	  
followed	  by	  protein	  boost	  have	  higher	  neutralization	  activity	  than	  a	  protein	  only,	  or	  a	  
vaccination	  primed	  with	  protein	  and	  followed	  by	  a	  DNA	  boost	  [25,26].	  	  
Even	  though	  the	  neutralization	  assay	  against	  the	  tier	  1	  viruses	  did	  not	  show	  any	  
neutralizing	  activity	  (Fig	  2.3),	  the	  assay	  was	  only	  performed	  prior	  to	  the	  protein	  boost.	  
The	  mouse	  sera	  neutralization	  assays	  against	  the	  tier	  2	  viruses	  in	  the	  global	  panel	  (Fig	  
2.4)	  were	  tested	  after	  the	  terminal	  bleed.	  Even	  though	  the	  majority	  of	  the	  
pseudoviruses	  analyzed	  were	  not	  neutralized,	  BJOX002000	  showed	  slight	  neutralization.	  
This	  is	  a	  promising	  result	  because	  it	  could	  indicate	  that	  if	  the	  serum	  IgG	  were	  further	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purified	  and	  concentrated,	  it	  may	  have	  additional	  neutralizing	  activity	  below	  the	  level	  of	  
detection	  for	  the	  sera	  assay.	  	  
Titers	  of	  rabbit	  serum	  following	  the	  DNA	  vaccination	  were	  undetectable	  (Fig	  2.6),	  
which	  was	  a	  highly	  unexpected	  result.	  However,	  after	  the	  protein	  boost,	  the	  titer	  
increased	  substantially.	  The	  titer	  after	  the	  first	  protein	  boost	  was	  ten	  fold	  higher	  than	  
the	  initial	  titer	  from	  a	  single	  protein	  immunization	  with	  SOSIP	  gp140	  ZnCh.	  The	  second	  
protein	  boost	  in	  this	  study	  produced	  a	  titer	  that	  was	  on	  par	  with	  a	  second	  gp140	  protein	  
only	  immunization	  (H.	  Shi,	  unpublished	  data).	  The	  rabbit	  neutralization	  assays	  against	  
the	  tier	  1	  viruses	  demonstrated	  some	  neutralization	  (Fig	  2.7);	  however,	  they	  were	  
performed	  after	  the	  second	  protein	  boost,	  so	  a	  direct	  comparison	  cannot	  be	  made	  
between	  mouse	  and	  rabbit	  assays.	  All	  three	  rabbits	  neutralized	  SF162.	  Only	  R2	  
neutralized	  Bal.26,	  and	  none	  of	  the	  rabbit	  sera	  were	  able	  to	  neutralize	  DH12.	  One	  
possibility	  for	  the	  low	  neutralization	  activity	  was	  that	  the	  serum	  nAb	  concentration	  was	  
below	  detection	  standards	  for	  this	  assay,	  and	  thus	  purified	  IgG	  could	  yield	  higher	  
neutralizing	  activity.	  This	  assay	  was	  not	  performed	  at	  this	  time	  because	  tier	  1	  
neutralization	  was	  not	  the	  overall	  goal	  of	  this	  study.	  We	  are	  more	  interested	  in	  the	  
neutralization	  ability	  against	  tier	  2	  viruses.	  
The	  tier	  2	  neutralization	  data	  (Fig	  2.8)	  did	  not	  demonstrate	  neutralization	  like	  
the	  tier	  1	  assays;	  however,	  due	  to	  the	  background	  from	  the	  serum	  components,	  it	  is	  
difficult	  to	  tell	  whether	  a	  higher	  concentration	  will	  yield	  better	  neutralization	  or	  not.	  The	  
rabbit	  serum	  could	  potentially	  have	  neutralizing	  activity	  at	  a	  higher	  concentration	  but	  
Abs	  would	  need	  to	  be	  purified	  from	  the	  serum	  to	  assess	  this	  claim.	  While	  we	  did	  not	  see	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any	  neutralization	  of	  the	  tier	  2	  viruses	  of	  the	  global	  panel	  viruses,	  we	  did	  see	  some	  
against	  the	  tier	  1	  viruses.	  This	  is	  a	  starting	  point	  for	  further	  studies	  into	  global	  panel	  
gene	  gun	  immunizations.	  	  
Further	  experiments	  should	  include	  a	  detailed	  peptide	  mapping	  of	  the	  V3	  region	  
of	  multiple	  different	  gp120	  constructs,	  ideally	  based	  on	  sequences	  native	  to	  the	  global	  
panel	  viruses,	  due	  to	  the	  variability	  in	  the	  immunized	  antigens.	  These	  epitope	  binding	  
sites	  should	  be	  compared	  to	  maps	  from	  rabbits	  immunized	  with	  SOSIP	  gp140	  ZnCh	  
alone	  to	  see	  how	  the	  DNA	  prime	  altered	  the	  binding	  repertoire	  of	  the	  Abs.	  
	  
Materials	  and	  Methods	  
Enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  
ELISAs	  were	  performed	  as	  previously	  described	  [27].	  The	  gp120	  or	  gp140	  was	  
coated	  onto	  96-­‐well	  Nunc-­‐Immuno	  plates	  and	  incubated	  at	  4°C	  overnight	  at	  a	  
concentration	  of	  30ng/well	  in	  coating	  buffer	  (15mM	  Na2CO3,	  35mM	  NaHCO3,	  3mM	  
NaN3,	  pH	  9.6).	  Plates	  were	  blocked	  with	  200μl	  of	  blocking	  buffer	  (PBS,	  pH	  7.4,	  2.5%	  skim	  
milk	  and	  5%	  calf	  serum)	  for	  1hr	  at	  37°C.	  Plates	  were	  washed	  five	  times	  with	  wash	  buffer	  
(PBS	  containing	  0.1%	  Tween	  20).	  	  
Serum	  was	  added	  1:300	  in	  blocking	  buffer	  for	  2hrs	  at	  37°C.	  Wells	  were	  
subsequently	  washed	  ten	  times	  with	  wash	  buffer.	  The	  secondary	  antibody	  (anti-­‐mouse-­‐
HRP	  or	  anti-­‐rabbit-­‐HRP)	  was	  added	  1:3000	  in	  blocking	  buffer,	  and	  incubated	  for	  1hr	  at	  
37°C.	  Wells	  were	  washed	  ten	  times	  again,	  then	  100uL	  of	  TMB	  substrate	  (BioRad)	  was	  
added.	  The	  plate	  was	  incubated	  for	  10min	  at	  room	  temperature	  (RT)	  and	  stopped	  using	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50uL	  of	  2N	  H2SO4.	  The	  absorbance	  was	  read	  at	  450nm	  on	  a	  microplate	  reader	  
(Versamax	  by	  Molecular	  Devices).	  All	  experiments	  were	  performed	  in	  duplicates.	  	  
	  
Gene	  gun	  bullets	  
Initially,	  20-­‐25mg	  of	  1.5micron	  gold	  particles	  were	  measured,	  then	  were	  quick	  
washed	  twice	  with	  500uL	  spermidine	  solution.	  Gold	  particles	  were	  resuspended	  in	  
150uL	  spermidine	  and	  transferred	  to	  a	  new	  1.5mL	  tube.	  2ug	  of	  plasmid	  DNA/	  mg	  of	  gold	  
was	  added	  to	  the	  tube	  while	  vortexing	  at	  a	  low	  speed.	  An	  equal	  amount	  (150uL)	  of	  10%	  
CaCl2	  was	  added	  while	  vortexing.	  The	  mixture	  was	  incubated	  for	  10min	  to	  allow	  the	  
gold	  to	  precipitate.	  	  
The	  polyvinylpyrrolidone	  (PVP)	  mixture	  (5%	  20x	  PVP	  in	  Ethanol	  (EtOH))	  is	  made	  
by	  first	  adding	  1mL	  of	  PVP/EtOH	  mixture	  to	  flat	  bottom	  vials	  per	  1mg	  gold.	  The	  mixture	  
is	  spun	  down	  at	  top	  speed	  for	  10	  seconds.	  The	  supernatant	  is	  removed,	  and	  the	  
DNA/gold	  mixture	  was	  washed	  3	  times	  with	  800uL	  EtOH	  while	  vortexing.	  The	  pellet	  was	  
resuspended	  in	  a	  small	  portion	  of	  the	  PVP/EtOH	  mixture	  (~500uL).	  This	  mixture	  was	  
transferred	  into	  the	  flat	  bottom	  vial.	  A	  2.5in	  section	  of	  tubing	  (0.125in	  x	  0.250in	  silicone	  
tubing)	  was	  cut	  and	  attached	  to	  a	  3mL	  syringe.	  A	  25in	  segment	  of	  the	  small	  tubing	  
(0.079in	  x	  0.098in	  Tefzel	  tubing)	  was	  cut	  and	  inserted	  in	  the	  tubing	  apparatus.	  The	  N2	  
tank	  was	  attached	  to	  the	  tubing	  apparatus	  and	  the	  flow	  was	  set	  to	  20PSI	  and	  the	  
flowmeter	  (Dywer	  VFA)	  to	  8	  liters/	  min	  (LPM)	  air.	  After	  pressing	  the	  load	  button,	  the	  vial	  
was	  mixed	  by	  vortexing	  and	  sonication,	  then	  the	  slurry	  was	  pulled	  into	  a	  3mL	  syringe.	  
The	  slurry	  was	  pushed	  into	  the	  end	  of	  the	  tubing	  apparatus	  and	  the	  spin	  cycle	  activated.	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Excess	  EtOH	  was	  collected	  as	  it	  was	  forced	  out	  of	  the	  apparatus.	  The	  tubing	  was	  allowed	  
to	  dry	  for	  at	  least	  1hr	  (N2	  flow	  through	  at	  20PSI).	  Finally,	  the	  tubing	  was	  cut	  into	  0.5in	  
pieces	  (bullets).	  Each	  bullet	  contains	  1ug	  of	  DNA.	  	  
	  
Animal	  immunizations	  
Female	  BALB/CJ	  mice	  were	  purchased	  from	  the	  Jackson	  Lab.	  Three	  non-­‐
overlapping	  gene	  gun	  shots	  were	  given	  to	  each	  animal	  on	  shaved	  abdominal	  skin.	  Blood	  
was	  collected	  from	  the	  lateral	  tail	  vein	  two	  weeks	  after	  each	  immunization.	  	  
Three	  New	  Zealand	  white	  female	  rabbits	  were	  purchased	  from	  Charles	  River	  
(USA).	  Six	  non-­‐overlapping	  shots	  were	  delivered	  to	  each	  animal	  on	  shaved	  abdominal	  
skin.	  Blood	  was	  collected	  from	  the	  central	  ear	  artery	  two	  weeks	  after	  each	  
immunization.	  All	  of	  the	  studies	  conducted	  were	  approved	  by	  IACUC.	  
	  
Neutralization	  assay	  	  
Virus	  neutralization	  assays	  were	  performed	  using	  single	  cycle	  HIV	  pseudovirus	  
infections	  of	  TZM-­‐	  bl	  cells	  as	  described	  elsewhere	  [27-­‐29].	  Heat	  inactivated	  rabbit	  sera	  
(56°C	  for	  1hr)	  was	  diluted	  in	  100μl	  of	  cell	  culture	  media	  (DMEM	  plus	  10%	  heat	  
inactivated	  FBS	  and	  1%	  penicillin/streptomycin).	  Samples	  were	  serially	  diluted	  from	  1:20	  
to	  1:43740	  in	  cell	  culture	  medium	  and	  pre-­‐incubated	  for	  1hr	  at	  37°C	  before	  adding	  cells.	  
After	  a	  48hr	  incubation,	  cells	  were	  lysed	  and	  luciferase	  activity	  determined	  using	  a	  
microtiter	  plate	  luminometer	  and	  Bright-­‐Glo	  Luciferase	  Assay	  System	  (Promega).	  
Neutralization	  titers	  are	  the	  sample	  dilution	  at	  which	  relative	  luminescence	  units	  (RLU)	  
29	  
were	  reduced	  by	  50%	  compared	  to	  RLU	  in	  virus	  control	  wells	  after	  subtraction	  of	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  Fuller	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  allowing	  us	  to	  use	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  gene	  gun	  and	  for	  
the	  training	  that	  you	  gave	  us	  with	  the	  equipment.	  
Panel	  of	  Global	  HIV-­‐1	  Env	  Clones	  (cat#	  12670)	  was	  obtained	  through	  the	  NIH	  
AIDS	  Reagent	  Program,	  Division	  of	  AIDS,	  NIAID,	  NIH	  from	  Dr.	  David	  Montefiori.	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Fig	  2.2:	  Mouse	  serum	  titer	  by	  week,	  measured	  by	  ELISA	  (a)	  against	  MCON6	  gp120	  















































































































































































































































































































































































































































































































































































































































Fig	  2.6:	  Rabbit	  serum	  titer	  by	  week,	  measured	  by	  ELISA	  (a)	  against	  MCON6	  gp120	  






















































Fig	  2.7:	  Rabbit	  tier	  1	  pseudovirus	  percent	  neutralization	  by	  serum	  dilution	  (a)	  SF162,	  (b)	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CHAPTER	  3:	  CONCLUSION	  AND	  FUTURE	  DIRECTIONS	  
	  
Conclusion	  
As	  discussed	  in	  Chapter	  2,	  global	  panel	  DNA	  immunizations	  followed	  with	  gp140	  
protein	  boosts	  did	  not	  elicit	  strong	  neutralization	  activity	  in	  mice	  or	  rabbit	  sera.	  The	  
inability	  of	  the	  sera	  to	  neutralize	  may	  be	  due	  to	  low	  levels	  of	  nAb	  present.	  We	  could	  
improve	  upon	  this	  study	  in	  several	  potential	  ways.	  One	  possibility	  is	  that	  the	  membrane	  
bound	  env	  is	  not	  as	  immunogenic	  as	  the	  secreted	  form.	  As	  reported	  from	  this	  
laboratory,	  when	  gp120	  protein	  alone	  was	  immunized,	  antigen	  specific	  titers	  of	  up	  to	  
107	  were	  observed	  [1].	  Thus,	  one	  possibility	  is	  to	  use	  plasmids	  that	  express	  secreted	  
versions	  of	  the	  global	  panel	  gp120	  subunit	  to	  induce	  a	  broad	  range	  of	  nAbs.	  	  
Alternatively,	  it	  is	  currently	  hypothesized	  that	  gp120	  alone	  may	  not	  be	  as	  ideal	  of	  an	  
immunogen,	  as	  the	  tendency	  to	  favor	  type-­‐specific	  nAbs	  and	  non-­‐nAb	  elicitation	  may	  
distract	  the	  immune	  system	  from	  potentially	  eliciting	  true	  bnAbs	  [1].	  Therefore,	  a	  
construct	  based	  on	  the	  gp160	  DNA	  plasmids,	  but	  modified	  to	  express	  gp140	  by	  deleting	  
the	  cytoplasmic	  tail	  and	  transmembrane	  region	  of	  the	  protein	  could	  also	  be	  used.	  This	  
may	  lead	  to	  a	  stronger	  immune	  response	  and	  therefore	  more	  antibodies,	  which	  could	  
induce	  greater	  numbers	  of	  nAbs.	  Another	  possibility	  would	  be	  to	  increase	  the	  amount	  of	  
DNA	  administered	  at	  each	  immunization.	  Other	  studies	  have	  immunized	  with	  36-­‐50ug	  
of	  DNA	  per	  immunization	  [2,3].	  Increasing	  the	  amount	  of	  DNA	  administered	  could	  
increase	  the	  Ab	  titers.	  The	  more	  DNA	  that	  can	  be	  introduced	  to	  the	  animal,	  the	  more	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cells	  that	  can	  uptake	  and	  express	  the	  plasmid	  protein.	  This	  increased	  expression	  should	  
lead	  to	  more	  Ab	  exposure	  and	  a	  better	  Ab	  response.	  	  
	  
Future	  Directions	  
Many	  different	  experiments	  could	  further	  clarify	  the	  results	  of	  this	  project	  in	  the	  
near	  future.	  The	  first	  step	  would	  be	  to	  purify	  the	  IgG	  from	  the	  rabbit	  serum	  and	  test	  the	  
neutralization	  activity	  against	  the	  global	  panel	  viruses	  using	  higher	  concentrations	  of	  
antibodies.	  This	  should	  also	  reduce	  the	  viral	  infectivity	  enhancement	  that	  seems	  to	  be	  
caused	  by	  some	  of	  the	  serum	  components.	  The	  purified	  IgG	  should	  also	  be	  tested	  
against	  a	  wider	  variety	  of	  tier	  1	  viruses,	  and	  compared	  to	  the	  neutralization	  activity	  of	  
gp140	  protein	  immunizations	  alone	  (H.	  Shi	  unpublished	  data).	  	  
Additionally,	  it	  is	  important	  to	  understand	  the	  exact	  binding	  locations	  of	  the	  
gp120/	  gp140	  specific	  antibodies.	  A	  peptide	  ELISA	  would	  show	  the	  binding	  location	  of	  
Abs	  that	  have	  a	  linear	  epitope.	  A	  standard	  peptide	  ELISA	  contains	  overlapping	  peptides	  
from	  a	  consensus	  sequence	  [4,5].	  Each	  well	  is	  coated	  with	  a	  different	  peptide	  and	  the	  
serum	  or	  purified	  IgG	  is	  added	  to	  each	  to	  test	  the	  ability	  to	  bind	  to	  that	  linear	  epitope.	  
Since	  this	  study	  used	  a	  wide	  variety	  of	  HIV	  strains,	  in	  addition	  to	  the	  consensus	  
sequence	  peptides,	  V3	  loop	  peptides	  specific	  to	  the	  global	  panel	  strains	  should	  be	  
tested.	  The	  results	  of	  the	  consensus	  sequence	  peptide	  mapping	  should	  be	  compared	  to	  
the	  results	  from	  our	  laboratory	  when	  rabbits	  were	  immunized	  with	  SOSIP	  gp140	  ZnCh	  
alone.	  This	  information	  may	  let	  us	  conclude	  whether	  or	  not	  the	  global	  panel	  DNA	  
immunization	  enhanced	  the	  breadth	  of	  Abs	  produced.	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APPENDIX	  A:	  PRELIMINARY	  GENE	  GUN	  DATA	  
	  
Conclusions	  
We	  first	  needed	  to	  establish	  that	  DNA	  immunization	  via	  gene	  gun	  would	  
successfully	  induce	  antibodies	  targeting	  HIV-­‐1	  immunogens	  in	  our	  lab,	  using	  this	  system.	  
The	  mice	  were	  immunized	  with	  DNA	  coding	  for	  an	  immunogen	  with	  demonstrated	  
efficacy	  in	  mice	  and	  rabbits.	  The	  first	  immunogen	  used	  was	  the	  engineered	  outer	  
domain	  GT6	  (eOD-­‐GT6)	  derived	  from	  gp120,	  followed	  by	  a	  larger	  immunogen,	  BG505	  
SOSIP-­‐gp140.	  This	  allowed	  a	  comparison	  of	  the	  immune	  response	  to	  previous	  studies	  
that	  we	  have	  done	  in	  our	  lab	  using	  these	  antigen	  [1].	  
The	  mice	  were	  immunized	  every	  two	  weeks	  for	  10	  weeks	  using	  2ug	  of	  DNA	  per	  
immunization	  (Fig	  A1).	  We	  immunized	  with	  eOD-­‐GT6	  for	  the	  first	  three	  immunizations,	  
and	  for	  the	  following	  three	  immunizations,	  we	  used	  SOSIP	  gp140.	  After	  the	  third	  
immunization,	  the	  antibody	  (Ab)	  titer	  reached	  to	  6x104	  (Fig	  A2).	  Additional	  
immunizations	  with	  gp140	  DNA	  did	  not	  further	  increase	  the	  Ab	  titer.	  The	  titer	  after	  the	  
terminal	  bleed	  (week	  12)	  dropped	  slightly	  to	  3x104.	  Thus,	  we	  confirmed	  that	  we	  could	  
successfully	  perform	  gene	  gun	  immunizations.	  
	  
Materials	  and	  Methods	  
























































































































Fig	  A2:	  Mouse	  serum	  titer	  by	  week,	  measured	  by	  ELISA	  against	  eOD-­‐GT6	  protein.	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APPENDIX	  B:	  HR1-­‐ID-­‐HR2	  
	  
Conclusions	  
The	  purpose	  of	  this	  experiment	  was	  to	  construct	  a	  protein	  that	  would	  be	  useful	  
as	  a	  treatment	  of	  HIV.	  We	  hypothesized	  that	  if	  we	  could	  create	  a	  construct	  that	  
mimicked	  the	  structure	  of	  HIV	  after	  it	  has	  entered	  a	  cell,	  we	  could	  target	  CD8	  T	  cells	  
toward	  infected	  cells	  and	  lyse	  them	  before	  too	  many	  new	  HIV	  virions	  were	  made.	  We	  
cloned	  the	  immunodominant	  (ID)	  region	  of	  an	  M	  group	  consensus	  (MCON6)	  region	  and	  
ligated	  it	  in	  between	  the	  heptad	  repeat	  1	  and	  2	  (HR1,	  HR2).	  The	  ID	  region	  is	  highly	  
immunogenic,	  and	  there	  should	  be	  high	  titers	  against	  this	  region	  of	  the	  protein	  when	  
used	  as	  an	  antigen.	  To	  that	  end,	  we	  would	  immunize	  either	  mice	  or	  rabbits	  and	  collect	  
their	  serum	  antibodies.	  We	  would	  then	  use	  these	  antibodies	  in	  an	  Antibody	  Dependent	  
Cellular	  Cytotoxicity	  (ADCC)	  assay	  to	  test	  the	  ability	  of	  the	  serum	  antibodies	  at	  activating	  
CD8	  T	  cell	  activity.	  	  
Following	  construction	  of	  HR1-­‐ID-­‐HR2,	  we	  tested	  binding	  of	  the	  two	  antibodies	  
known	  to	  bind	  to	  the	  six	  helix	  bundle,	  NC-­‐1	  and	  our	  2C2	  [1]	  (Fig	  B1),	  against	  HR1-­‐ID-­‐HR2	  
and	  HR1-­‐54Q.	  It	  is	  not	  surprising	  that	  2C2	  did	  not	  bind	  to	  HR1-­‐ID-­‐HR2,	  because	  three	  
quarters	  of	  its	  binding	  region	  was	  not	  included	  in	  the	  protein	  construct	  because	  is	  not	  
considered	  part	  of	  the	  ID	  region	  (Fig	  B2).	  In	  contrast,	  2C2	  was	  readily	  able	  to	  bind	  the	  
HR1-­‐54Q	  (unpublished	  data)	  construct,	  as	  the	  epitope	  was	  fully	  intact.	  NC-­‐1	  binds	  to	  
HR1-­‐ID-­‐HR2,	  but	  less	  so	  than	  it	  does	  to	  HR1-­‐54Q.	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The	  plans	  for	  this	  construct	  include	  immunizing	  either	  mice	  or	  rabbits,	  and	  
evaluating	  the	  antibodies	  produced	  on	  their	  ability	  to	  activate	  ADCC.	  The	  protein	  will	  be	  
loaded	  onto	  ZnCh	  and	  immunized	  subcutaneously.	  	  
	  
Materials	  and	  Methods	  
HR1-­‐ID-­‐HR2	  cloning	  
The	  immune-­‐dominant	  region	  of	  HIV-­‐1	  MCON6	  was	  PCR	  amplified	  using	  primers	  
(forward:	  aaaggaTCCGGCATCGTGCAGCAGCAGTCCAACCTGCTGCGG	  reverse:	  
aaaGAATTCttaatggtgatgatggtgatgCTCGTTCTTCTCCTGCTGG)	  with	  a	  BamHI	  and	  an	  EcoRI	  
site	  (respectively)	  inserted	  for	  digestions.	  It	  was	  then	  ligated	  into	  the	  pET	  vector	  
containing	  the	  HR1-­‐HR2	  domains	  (pET	  54Q	  trimer	  vector)	  using	  standard	  molecular	  
biology	  techniques.	  	  
	  
Protein	  expression	  
The	  ligated	  plasmids	  were	  transformed	  into	  T7	  competent	  cells	  (New	  England	  
Biolabs)	  for	  E.	  coli	  expression.	  A	  small	  volume	  of	  LB	  was	  inoculated	  with	  a	  single	  colony	  
from	  the	  transformed	  E.	  coli	  cells.	  The	  next	  day,	  the	  cultures	  were	  used	  to	  inoculate	  a	  
large	  volume	  of	  LB.	  Once	  the	  optical	  density	  value	  (OD)	  reached	  an	  OD600	  level	  of	  1,	  the	  
cultures	  were	  induced	  with	  1mM	  isopropyl-­‐beta-­‐D-­‐thiogalactopyranoside	  (IPTG).	  After	  




Cell	  lysis	  	  
The	  pellet	  was	  resuspended	  in	  phosphate	  buffered	  saline	  (PBS)	  and	  vortexed.	  
The	  suspension	  was	  transferred	  into	  a	  glass	  beaker	  for	  sonication	  (10min	  at	  63%	  Amp,	  
40sec	  on,	  20sec	  off).	  The	  cells	  were	  lysed	  using	  the	  French	  Press,	  one	  time	  at	  20000PSI.	  
The	  lysed	  cells	  were	  spun	  down	  at	  10000RPM	  for	  10min	  then	  the	  pellet	  was	  
resuspended	  in	  8M	  urea.	  The	  supernatant	  was	  then	  spun	  down	  again.	  	  
	  
Protein	  purification	  
To	  purify	  the	  HR1-­‐ID-­‐HR2	  protein,	  the	  supernatant	  of	  the	  cell	  lysis	  was	  mixed	  
end-­‐to-­‐end	  with	  Ni-­‐NTA	  beads	  overnight.	  The	  mixture	  was	  allowed	  to	  flow	  through	  a	  
column	  two	  times.	  The	  beads	  were	  then	  washed	  with	  a	  decreasing	  concentration	  of	  
urea	  (8M,	  6M,	  4M,	  2M,	  1M)	  100mL	  each,	  then	  with100mL	  of	  40mM	  imidazole	  in	  PBS.	  
The	  protein	  was	  eluted	  with	  250mM	  in	  10mL	  PBS.	  	  
	  
Protein	  dialysis	  
The	  protein	  was	  dialyzed	  to	  remove	  the	  imidazole.	  To	  dialyze,	  the	  solution	  was	  
loaded	  into	  Spectra/	  Por	  molecularporous	  membrane	  tubing	  (size	  3,	  MWCO:	  3500,	  
spectrumlabs)	  with	  10%	  glycerol.	  The	  buffer	  was	  20mM	  Hepes,	  25mM	  NaCl,	  and	  10%	  
glycerol.	  They	  were	  allowed	  to	  dialyze	  at	  room	  temperature,	  and	  the	  buffer	  was	  
changed	  every	  3hr,	  at	  least	  3	  times.	  The	  solution	  was	  then	  removed	  from	  the	  dialysis	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